Иммунотерапия рецидивного немелкоклеточного рака легкого в первой линии

СтатьяМЕД СОВЕТ. 2019; № 19: 132–136. DOI:10.21518/2079-701X-2019-19-132-136

Родионов Е.О.^[1]

Миллер С.В.

Тузиков С. А.^[1]

Ефтеев Л.А.

Маркович В.А.

Миллер Д.С.^[1]

^[1]Сибирский государственный медицинский университет (Томск)

иммунотерапия

пембролизумаб

немелкоклеточный рак легкого

аутоиммунный гипотиреоз

Легкие

Новообразования

Цыганов М.М., Родионов Е.О., Дерюшева И.В., Миллер С.В., Ибрагимова М.К., Писарева Л.Ф. и др. Оценка прогностической значимости экспрессии генов монорезистентности в опухоли больных немелкоклеточным раком легкого после предоперационной химиотерапии. Вопросы онкологии. 2017;63(1):122–125. Режим доступа: https://voprosyonkologii.ru/index.php/journal/article/view/349/349.https://voprosyonkologii.ru/index.php/journal/article/view/349/349

Rodionov E.O., Miller S.V., Tuzikov S.A., et al. 1370PThe results of treatment of non-small cell lung cancer stage III with a preoperative vinorelbine/carboplatin and personalized adjuvant chemotherapy. Ann Oncol. 2018;29(8):viii490. doi: 10.1093/annonc/mdy291.007..
DOI: 10.1093/annonc/mdy291.007

Postmus P.E., Kerr K.M., Oudkerk M., Senan S., Waller D.A., Vansteenkiste J. et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv1–iv21. doi: 10.1093/annonc/mdx222..
DOI: 10.1093/annonc/mdx222

Leventakos K., Mansfield A.S. Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. BioDrugs. 2016;30(5):397-405. doi: 10.1007/s40259-016-0187-0..
DOI: 10.1007/s40259-016-0187-0

Sul J., Blumenthal G.M., Jiang X., He K., Keegan P., Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed DeathLigand 1. Oncologist. 2016;21(5):643-650. doi: 10.1634/theoncologist.2015-0498..
DOI: 10.1634/theoncologist.2015-0498

Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;(346):92-98. doi: 10.1056/NEJMoa011954..
DOI: 10.1056/NEJMoa011954

Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;(22):1589-1597. doi: 10.1200/JCO.2004.08.163..
DOI: 10.1200/JCO.2004.08.163

Shepherd F.A., Dancey J., Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103. doi: 10.1200/JCO.2000.18.10.2095..
DOI: 10.1200/JCO.2000.18.10.2095

Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med. 2005;353(2):123-132. doi: 10.1056/NEJMoa050753..
DOI: 10.1056/NEJMoa050753

Herbst R.S., Baas P., Kim D.-W., Felip E., PérezGracia J.L., Han J.-Y. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7..
DOI: 10.1016/S0140-6736(15)01281-7

Chatterjee M., Turner D.C., Felip E., Lena H., Cappuzzo F., Horn L. et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol. 2016;27(7):1291–1298. doi: 10.1093/annonc/mdw174..
DOI: 10.1093/annonc/mdw174

Reck M., Rodríguez-Abreu D., Robinson A.G., Hui R., Csőszi T., Fülöp A. et al. Pembrolizumab versus сhemotherapy for PD-L1–positive non–small cell lung cancer. N Engl J Med. 2016;375(19):1823-1833. doi: 10.1056/NEJMoa1606774..
DOI: 10.1056/NEJMoa1606774

Reck A.M., Rodrigues-Abreu D., Robinson A.G., Hui R., et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non – small-cell lung cancer with PD-L1 tumor proportion score of 50[%] or greater. J Clin Oncol. 2019;37(7):537-546. doi: 10.1200/JCO.18.00149..
DOI: 10.1200/JCO.18.00149

Qin A., Street L., Cease K., Viglianti B., Warren E. et al. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18(5):559-564. doi: 10.1016/j.cllc.2017.01.012..
DOI: 10.1016/j.cllc.2017.01.012

Язык текста: Русский

ISSN: 2079-701X